Navigation Links
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Date:9/20/2007

king statements, including statements about the regulatory plans and timing for, and the expansion of, the Campath product label into earlier-line CLL, high-risk CLL, and combination and consolidation therapy. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: the actual efficacy and safety of Campath in these indications; the actual timing and content of submissions to and decisions made by the U.S. Food and Drug Administration and other regulatory authorities, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports to the Frankfurt Stock Exchange and in our reports filed with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to
'/>"/>

SOURCE Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. New Microarray Labeling Kit for Preparing cDNA Probes
9. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
10. aRNA Synthesis and Labeling for Array Analysis
11. Amino Allyl Labeling for Array Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised ... secured Otter Capital as a significant new partner. Otter ... GGI’s Agriplier™ technology, building on recent compelling field trial ... first meeting, we have been impressed with Otter Capital’s ... Alan Sobba, President and CEO of GGI. “We look ...
(Date:8/27/2014)... California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security LLC ... to develop and deliver a state-of-the-art laser system ... facility (ELI Beamlines), under construction in the Czech ... performance, the laser system, called the " High ...
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
(Date:8/27/2014)... 27, 2014 The Global and China ... on the current state of the Trifluoroacetic Acid industry ... basic overview of the industry, including definitions, applications and ... market analysis are provided with a focus on history, ... comparison between the international and Chinese situation is also ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... EMERYVILLE, Calif., Oct. 10 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... call on Monday, October 13, to provide an update ... ischemic stroke.,Hosting the call will be Paul E. Freiman, ... medical officer., -- Date: Monday, October 13, ...
... CSMG,Technologies, Inc., (OTC Bulletin Board: CTGI), ... received approval of its fifth U.S.,patent. The ... for "Bonding of,Soft Biological Tissues by Passing ... subsidiary Live Tissue Connects ("LTC"),platform tissue bonding/welding ...
... Calif., Oct. 10 Finesse Solutions, LLC, a,manufacturer ... process,applications, is pleased to announce improvements to their ... even easier. The E-Store,can be found at the ... easily purchase bioprocess sensors and accessories,on-line, anywhere in ...
Cached Biology Technology:Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 3
(Date:8/28/2014)... Researchers at the University of Minnesota have developed an ... be used for muscle regeneration research as well as ... , The research is published in the current edition ... is no treatment for FSHD, which is thought by ... dystrophy. FSHD is an unusual genetic disorder because, unlike ...
(Date:8/28/2014)... A unique method for delivering compounds that ... HIV and AIDS may be possible, thanks ... Agricultural Sciences., A semi-soft vaginal suppository made ... loaded with the antiviral drug Tenofovir provides ... against the spread of sexually transmitted infections ...
(Date:8/28/2014)... More than 25 million kilometres of new roads will ... will slice into Earth,s last wildernesses, where they bring ... , Now, an ambitious study has created a ... to try to balance the competing demands of development ... an ,environmental-values, layer that estimates that natural importance of ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Durham University have discovered a natural mechanism in plants that ... to better crop yields. Plants naturally slow their growth ... such as water shortage or high salt content in soil, ... making proteins that repress the growth of the plant. This ...
... vehicles that have fish-like sensations, advanced ship design and ... Research (ONR) on Dec. 23 learned they will receive ... The researchers have been selected for Presidential Early ... be honored at a ceremony at the White House ...
... genetic signature that implicates a key mechanism in the immune ... leukaemia. Acute lymphoblastic leukaemia or ALL is the most ... leukaemia for one in four ALL patients is a mutation ... fuse together. This genomic alteration happens before birth and kick ...
Cached Biology News:New discovery could stimulate plant growth and increase crop yields, researchers say 2White House lauds ONR-funded researchers for early success 2Immune system development linked to leukemia 2Immune system development linked to leukemia 3
... cells (BTI-TN-5B1-4) derived from Trichoplusia ni ... to be capable of expressing significantly ... compared to other insect cells. High ... doubling time as adherent cultures- Quick adaptation ...
... steadylite plus assay system offers ... sensitivity, Designed for batch-processing systems, ... higher density microplates such as ... free, Convenient storage conditions ( ...
... lysis buffer, PCR mix, DNA polymerase and ... volume PCR reactions. This system can detect ... rod and coccus bacteria, such as Escherichia ... Streptococcus Agalactiae, and etc. With the powerful ...
... Kit is uniquely formulated to give ... protein modification for optimal mass spectrometry ... with traditional silver stains are eliminated ... reagents used do not modify protein ...
Biology Products: